Continuous Bioprocessing Market Size, Share & Trends Analysis Report By Product (Instruments, Consumables & Reagents), By Application (Monoclonal Antibodies, Vaccines), By End Use, By Region, And Segment Forecasts, 2025 - 2030

Continuous Bioprocessing Market Growth & Trends

The global continuous bioprocessing market size is anticipated to reach USD 911.43 million by 2030, growing at a CAGR of 18.63% from 2025 to 2030, according to a new report by Grand View Research, Inc. The continuous bioprocessing market is driven by the increasing demand for biologics, biosimilars, and advanced therapies such as cell and gene therapies and monoclonal antibodies (mAbs). As pharmaceutical and biotechnology companies seek higher efficiency, reduced costs, and faster production cycles, continuous bioprocessing has emerged as a key solution. Compared to traditional batch processing, continuous bioprocessing offers higher productivity, better scalability, and improved process control, making it essential for large-scale biologics manufacturing. Additionally, advancements in single-use bioreactors, perfusion-based systems, and process analytical technologies (PAT) are accelerating the adoption of continuous bioprocessing across the industry.

The COVID-19 pandemic acted as a major catalyst for the adoption of continuous bioprocessing, as the need for rapid vaccine production, scalable manufacturing, and efficient supply chains intensified. Companies developing mRNA vaccines, monoclonal antibodies, and antiviral therapies turned to continuous bioprocessing to meet global demand while maintaining high product quality. The pandemic also highlighted vulnerabilities in traditional batch processing, leading to increased investments in flexible, scalable, and automated continuous biomanufacturing solutions. As a result, post-pandemic, many biopharma companies have continued to invest in continuous bioprocessing technologies, ensuring long-term market growth and resilience in global biomanufacturing.

The increasing collaboration between biopharma companies, CMOs, and regulatory agencies is also driving market growth. Regulatory bodies such as the FDA and EMA have been actively supporting the shift towards continuous manufacturing by providing guidelines, incentives, and faster approval pathways. Moreover, key players are investing heavily in automation, AI-driven process monitoring, and real-time analytics, further optimizing production workflows. The integration of continuous chromatography, inline quality control, and modular bioreactor systems is streamlining biologics manufacturing, reducing variability, and ensuring consistent product quality.

Continuous Bioprocessing Market Report Highlights

• Based on product, consumables & reagents dominated the market in 2024. The shift from traditional batch processing to continuous bioprocessing has led to a growing demand for continuous bioprocessing consumables& reagents
• Based on application, the monoclonal antibodies segment dominated the market, with the largest revenue share of 29.98% in 2024. The shift toward biosimilars and regulatory support for process intensification further fuel adoption, as manufacturers seek to reduce production costs while maintaining high product purity and potency
• Based on end use, pharmaceutical and biotechnology companies dominated the market, with the largest revenue share of 48.43% in 2024. The regulatory support from agencies like the FDA and EMA for continuous manufacturing and process intensification is further encouraging biopharma firms to invest in next-generation bioprocessing solutions
• In 2024, North America led the market, accounting for the largest revenue share of 37.46%. This dominance is fueled by significant investments in biopharmaceutical R&D, a well-established manufacturing infrastructure, and favorable regulatory policies supporting advanced bioprocessing technologies.